Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. More Details
+ 1 more risk
Excellent balance sheet with limited growth.
Share Price & News
How has Mersana Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MRSN's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: MRSN exceeded the US Biotechs industry which returned 33.6% over the past year.
Return vs Market: MRSN exceeded the US Market which returned 18.3% over the past year.
Price Volatility Vs. Market
How volatile is Mersana Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StHow Much Is Mersana Therapeutics' (NASDAQ:MRSN) CEO Getting Paid?
1 month ago | Simply Wall StIs Mersana Therapeutics (NASDAQ:MRSN) Using Too Much Debt?
2 months ago | Simply Wall StHow Much Are Mersana Therapeutics, Inc. (NASDAQ:MRSN) Insiders Spending On Buying Shares?
Is Mersana Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate MRSN's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate MRSN's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: MRSN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: MRSN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MRSN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MRSN is overvalued based on its PB Ratio (4.6x) compared to the US Biotechs industry average (3.4x).
How is Mersana Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MRSN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MRSN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MRSN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MRSN's revenue (80.5% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: MRSN's revenue (80.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MRSN is forecast to be unprofitable in 3 years.
How has Mersana Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MRSN is currently unprofitable.
Growing Profit Margin: MRSN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MRSN is unprofitable, and losses have increased over the past 5 years at a rate of 26.6% per year.
Accelerating Growth: Unable to compare MRSN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MRSN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.1%).
Return on Equity
High ROE: MRSN has a negative Return on Equity (-25.5%), as it is currently unprofitable.
How is Mersana Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: MRSN's short term assets ($294.9M) exceed its short term liabilities ($22.4M).
Long Term Liabilities: MRSN's short term assets ($294.9M) exceed its long term liabilities ($14.5M).
Debt to Equity History and Analysis
Debt Level: MRSN's debt to equity ratio (1.8%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if MRSN's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MRSN has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: MRSN has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 42.5% each year
What is Mersana Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MRSN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MRSN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MRSN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MRSN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MRSN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Anna Protopapas (56 yo)
Ms. Anna Protopapas has been the Chief Executive Officer and President of Mersana Therapeutics, Inc. since March 2015. Ms. Protopapas has extensive strategic leadership experience and a demonstrated track ...
CEO Compensation Analysis
Compensation vs Market: Anna's total compensation ($USD1.74M) is below average for companies of similar size in the US market ($USD4.43M).
Compensation vs Earnings: Anna's compensation has been consistent with company performance over the past year.
|Senior Vice President of Finance & Product Strategy||1.25yrs||US$1.09m||0% |
|Chief Medical Officer||1.92yrs||US$1.15m||0% |
|Co-Founder||no data||no data||no data|
|VP, Controller & Principal Accounting Officer||1.08yrs||no data||no data|
|Chief Science & Technology Officer||1.75yrs||US$1.05m||0.025% |
|Executive Director of Investor Relations & Corporate Communications||1.92yrs||no data||no data|
|Vice President of Legal Operations||no data||no data||no data|
|Chief Manufacturing Officer||4.67yrs||no data||no data|
|Senior Vice President of Regulatory Affairs||0.17yr||no data||no data|
Experienced Management: MRSN's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
|Independent Chairman||8.25yrs||US$149.24k||0.79% |
|Independent Director||3.08yrs||US$126.57k||0.0016% |
|Independent Director||2.58yrs||US$123.07k||0% |
|Independent Director||4.17yrs||US$110.62k||0% |
|Independent Director||3.75yrs||US$118.12k||0% |
|Board Observer||no data||no data||no data|
|Independent Director||0.50yr||no data||no data|
Experienced Board: MRSN's board of directors are considered experienced (3.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 43.1%.
Mersana Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Mersana Therapeutics, Inc.
- Ticker: MRSN
- Exchange: NasdaqGS
- Founded: 2001
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.264b
- Shares outstanding: 68.42m
- Website: https://www.mersana.com
Number of Employees
- Mersana Therapeutics, Inc.
- 840 Memorial Drive
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|MRSN||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Jun 2017|
|0M4||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jun 2017|
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a p ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/25 01:10|
|End of Day Share Price||2020/10/23 00:00|